Entrada’s stock drops as DMD drug’s efficacy falls short
Entrada Therapeutics’ stock value has dropped by more than 57% after the efficacy of its Duchenne muscular dystrophy (DMD) therapy,…
All articles by Annabel Kartal Allen
Annabel Kartal Allen
Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel
-
-
DDW 2026: key readouts from the conference
At the 2026 Digestive Disease Week (DDW) conference, there was significant buzz around certain pharma and medical device readouts, with…
-
J&J’s soft tissue surgical robot succeeds in pivotal gastric bypass study
Johnson & Johnson (J&J) is eyeing a De Novo classification from US regulators for its Ottava Robotic Surgical System, after…
-
Iterative Health banks $77m to level up AI-driven clinical research tech
Iterative Health has netted $77m in a Series C funding round to expand and scale its artificial intelligence (AI)-powered clinical…
-
Patient death puts Newron’s late-stage schizophrenia trial on ice
US regulators have pressed pause on enrolment to Newron Pharmaceuticals’ Phase III trial on lead schizophrenia candidate, evenamide, after a…
-
EnteroBiotix nets $25m to progress microbiome-based IBS drug
Investors have gone with their gut on EnteroBiotix’s microbiome-based lead therapy, EBX-102-02, pledging £19m ($25m) to fund a mid-stage trial…
-
Veradermics’ stock grows on pivotal hair loss win
Veradermics’ share price has jumped more than 47% after its oral, extended-release version of minoxidil posted a win during a…
-
HRS 2026: Medtronic, Boston Scientific and Abbott debut key PFA data
Boston Scientific, Abbott and Medtronic all presented successful readouts of their cardiac devices during the Heart Rhythm Society’s (HRS) 2026…
-
Non-animal testing goes mainstream, but success hinges on smart use
As new approach methodologies (NAMs) burst onto the scene amid the wider shift away from animal testing, biotech and pharma…
-
Paradigm Health debuts post-marketing study tool for routine care integration
Clinical trials technology specialist Paradigm Health has introduced a new, late-phase clinical evidence generation platform, which sets out to streamline…